Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar P, Geirnaert M, Gavura S, Beca J, Mercer RE, Denburg A, Muñoz C, Tadrous M, Parmar A, Dionne F, Boehm D, Chambers C, Craig E, Trudeau M, Cheung MC, Houlihan J, McDonald V, Pechlivanoglou P, Taylor M, Wasylenko E, Wranik WD, Chan KKW. Takhar P, et al. Among authors: gavura s. Curr Oncol. 2024 Apr 1;31(4):1876-1898. doi: 10.3390/curroncol31040141. Curr Oncol. 2024. PMID: 38668044 Free PMC article.
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K, Nam S, Evans B, de Oliveira C, Chambers A, Gavura S, Hoch J, Mercer RE, Dai WF, Beca J, Tadrous M, Isaranuwatchai W. Chan K, et al. Among authors: gavura s. BMJ Open. 2020 Jan 7;10(1):e032884. doi: 10.1136/bmjopen-2019-032884. BMJ Open. 2020. PMID: 31915169 Free PMC article.
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, Beca J, Bouchard S, Chambers C, Hunt MJ, Husereau D, Lungu E, McDonald V, Mercer RE, Mitera G, Muñoz C, Naipaul R, Peacock S, Potashnik T, Tadrous M, Takhar P, Taylor M, Trudeau M, Wasney D, Gavura S, Chan KKW. Parmar A, et al. Among authors: gavura s. Curr Oncol. 2023 Mar 28;30(4):3776-3786. doi: 10.3390/curroncol30040286. Curr Oncol. 2023. PMID: 37185399 Free PMC article.
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM, Parmar A, Guo H, Schwartz D, Isaranuwatchai W, Beca J, Dai W, Arias J, Gavura S, Chan KKW. Phillips CM, et al. Among authors: gavura s. Cancer. 2020 Apr 15;126(8):1717-1726. doi: 10.1002/cncr.32697. Epub 2020 Jan 8. Cancer. 2020. PMID: 31913522 Free article.
Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J, Dai WF, Trudeau M, Mercer RE, Naipaul R, Wright FC, Ferguson SE, Darling G, Gavura S, Eisen A, Kouroukis CT, Beca J, Chan KKW. Keech J, et al. Among authors: gavura s. Int J Technol Assess Health Care. 2020 Aug 11:1-6. doi: 10.1017/S0266462320000483. Online ahead of print. Int J Technol Assess Health Care. 2020. PMID: 32779560
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V, Luo J, Parmar A, Dai WF, Beca JM, Raphael MJ, Isaranuwatchai W, Habbous S, Tadrous M, Earle CC, Biagi JJ, Mittmann N, Arias J, Gavura S, Chan KKW. Arciero V, et al. Among authors: gavura s. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac047. doi: 10.1093/jncics/pkac047. JNCI Cancer Spectr. 2022. PMID: 35758620 Free PMC article.
33 results